HBM Holdings Limited announced a significant legal victory regarding its patent entitled "Binding Molecule" (Patent Application No. CN201210057668.0). The China National Intellectual Property Administration upheld the patent following an invalidation request by Biocytogen Pharmaceuticals. This decision affirms HBM Holdings' rights to its innovative method for producing fully human heavy chain-only antibodies using transgenic animals. The company plans to continue utilizing its patented technology to advance transformative therapies globally.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on June 16, 2025, and is solely responsible for the information contained therein.